{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:57:48Z","timestamp":1790639868418,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Center Talent Development Program","award":["2025RCQN09"],"award-info":[{"award-number":["2025RCQN09"]}]},{"name":"Clinical Collaboration Project of Integrated Traditional Chinese and Western Medicine for Major Difficult Diseases","award":["ZDYN-2024-A-155"],"award-info":[{"award-number":["ZDYN-2024-A-155"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05097-w","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:26:17Z","timestamp":1783131977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis"],"prefix":"10.1186","volume":"26","author":[{"given":"Shanshan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"2","key":"5097_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89\u2013102.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"5097_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22(3):268\u201382.","journal-title":"Lancet Neurol"},{"issue":"12","key":"5097_CR3","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128\u201338.","journal-title":"Brain"},{"key":"5097_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"5097_CR5","doi-asserted-by":"publisher","first-page":"e200291","DOI":"10.1212\/NXI.0000000000200291","volume":"11","author":"G Volpe","year":"2024","unstructured":"Volpe G, Jurkute N, Girafa G, Zimmermann HG, Motamedi S, Bereuter C, Pandit L, D\u2019Cunha A, Yeaman MR, Smith TJ, et al. Diagnostic value of inter-eye difference metrics on OCT for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2024;11(6):e200291.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"5097_CR6","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","volume":"38","author":"N Jeyakumar","year":"2024","unstructured":"Jeyakumar N, Lerch M, Dale RC, Ramanathan S. MOG antibody-associated optic neuritis. Eye (Lond). 2024;38(12):2289\u2013301.","journal-title":"Eye (Lond)"},{"issue":"3","key":"5097_CR7","doi-asserted-by":"publisher","first-page":"e200240","DOI":"10.1212\/NXI.0000000000200240","volume":"11","author":"GT Park","year":"2024","unstructured":"Park GT, Galetta S. Distinguishing between myelin oligodendrocyte glycoprotein disease optic neuritis and nonarteritic anterior ischemic optic neuropathy. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200240.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"5097_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratre S, Vincent A, Palace J. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276\u201383.","journal-title":"JAMA Neurol"},{"issue":"6","key":"5097_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474\u201381.","journal-title":"Neurology"},{"issue":"5","key":"5097_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","volume":"79","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2022;79(5):518\u201325.","journal-title":"JAMA Neurol"},{"issue":"2","key":"5097_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","volume":"106","author":"M Yang","year":"2022","unstructured":"Yang M, Wu Y, Lai M, Song H, Li H, Sun M, Xie L, Zhou H, Xu Q, Wei S, et al. Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study. Br J Ophthalmol. 2022;106(2):262\u20136.","journal-title":"Br J Ophthalmol"},{"key":"5097_CR12","doi-asserted-by":"crossref","unstructured":"Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Pratico AD, Annovazzi P, Cordani R, Cordelli DM, Crichiutti G et al. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm 2023, 10(1).","DOI":"10.1212\/NXI.0000000000200065"},{"issue":"12","key":"5097_CR13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","author":"The clinical profile of optic neuritis","year":"1991","unstructured":"The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12):1673\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"5097_CR14","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21(12):1120\u201334.","journal-title":"Lancet Neurol"},{"issue":"3","key":"5097_CR15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities hand motion and counting fingers can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5097_CR16","volume-title":"Chinese Guidelines for Prevention and Control of Overweight and Obesity in Adults (2021 Edition)","author":"Adults","year":"2021","unstructured":"Adults, RCoGfPaCoOaOi. Chinese guidelines for prevention and control of overweight and obesity in adults (2021 Edition). Beijing: People\u2019s Medical Publishing House; 2021."},{"issue":"10","key":"5097_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","volume":"81","author":"YN Kwon","year":"2024","unstructured":"Kwon YN, Kim B, Kim JS, Park KS, Seo DY, Kim H, Lee EJ, Lim YM, Ju H, Chung YH, et al. Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2024;81(10):1073\u201384.","journal-title":"JAMA Neurol"},{"key":"5097_CR18","doi-asserted-by":"crossref","unstructured":"Cao S, Zhang Y, Xu X, Sun M, Pan C, Wang Y, Wei S, Xu Q, Zhou H. Antibodies to myelin oligodendrocyte glycoprotein in optic perineuritis. Front Immunol 2025, 16.","DOI":"10.3389\/fimmu.2025.1657600"},{"key":"5097_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","volume":"400","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M, Xu Q, Sun M, Wei S. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China. J Neurol Sci. 2019;400:83\u20139.","journal-title":"J Neurol Sci"},{"issue":"1","key":"5097_CR20","doi-asserted-by":"publisher","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","volume":"5","author":"C Satukijchai","year":"2022","unstructured":"Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open. 2022;5(1):e2142780.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"5097_CR21","doi-asserted-by":"publisher","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","volume":"11","author":"S Huda","year":"2021","unstructured":"Huda S, Whittam D, Jackson R, Karthikeayan V, Kelly P, Linaker S, Mutch K, Kneen R, Woodhall M, Murray K, et al. Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open. 2021;11(11):e055392.","journal-title":"BMJ Open"},{"issue":"1","key":"5097_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jnnp-2024-333464","volume":"96","author":"A Virupakshaiah","year":"2024","unstructured":"Virupakshaiah A, Schoeps VA, Race J, Waltz M, Sharayah S, Nasr Z, Moseley CE, Zamvil SS, Gaudioso C, Schuette A, et al. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024;96(1):68\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"5097_CR23","doi-asserted-by":"publisher","first-page":"e200309","DOI":"10.1212\/NXI.0000000000200309","volume":"11","author":"Y Xu","year":"2024","unstructured":"Xu Y, Meng H, Fan M, Yin L, Sun J, Yao Y, Wei Y, Cong H, Wang H, Song T, et al. A simple score (MOG-AR) to identify individuals at high risk of relapse after mogad attack. Neurol Neuroimmunol Neuroinflamm. 2024;11(6):e200309.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"5097_CR24","doi-asserted-by":"publisher","first-page":"102468","DOI":"10.1016\/j.autrev.2020.102468","volume":"19","author":"J Merrheim","year":"2020","unstructured":"Merrheim J, Villegas J, Van Wassenhove J, Khansa R, Berrih-Aknin S, le Panse R, Dragin N. Estrogen, estrogen-like molecules and autoimmune diseases. Autoimmun Rev. 2020;19(3):102468.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"5097_CR25","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1172\/JCI73408","volume":"124","author":"L Cruz-Orengo","year":"2014","unstructured":"Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, Piccio L, Schmidt RE, Cross AH, Crosby SD, et al. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J Clin Invest. 2014;124(6):2571\u201384.","journal-title":"J Clin Invest"},{"key":"5097_CR26","doi-asserted-by":"publisher","first-page":"8871146","DOI":"10.1155\/2020\/8871146","volume":"2020","author":"S Mori","year":"2020","unstructured":"Mori S, Kurimoto T, Murai Y, Ueda K, Sakamoto M, Chihara N, Yamada-Nakanishi Y, Nakamura M. Efficacy for the annual relapse rate after the immunosuppressive therapy in patients associated with anti-AQP4 or anti-MOG antibody-positive optic neuritis. J Ophthalmol. 2020;2020:8871146.","journal-title":"J Ophthalmol"},{"issue":"2","key":"5097_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5097_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","volume":"239","author":"M Yang","year":"2022","unstructured":"Yang M, Wu Y, Song H, Lai M, Li H, Sun M, Zhao J, Fu J, Xu X, Xie L, et al. Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies. Am J Ophthalmol. 2022;239:11\u201325.","journal-title":"Am J Ophthalmol"},{"key":"5097_CR29","doi-asserted-by":"crossref","unstructured":"Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, Zhang W, Li J, Ren X, Fang F et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm 2020;7(3).","DOI":"10.1212\/NXI.0000000000000705"},{"key":"5097_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, Flet-Berliac L, de Chalus A, Adamsbaum C, Capobianco M, et al. E.U. paediatric MOG consortium consensus: Part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"5097_CR31","doi-asserted-by":"publisher","first-page":"e209624","DOI":"10.1212\/WNL.0000000000209624","volume":"103","author":"R Deschamps","year":"2024","unstructured":"Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, et al. Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study. Neurology. 2024;103(3):e209624.","journal-title":"Neurology"},{"issue":"4","key":"5097_CR32","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1007\/s00415-021-10764-7","volume":"269","author":"H Masuda","year":"2022","unstructured":"Masuda H, Mori M, Yokouchi H, Uzawa A, Uchida T, Muto M, Ohtani R, Aoki R, Yamamoto S, Kuwabara S. Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. J Neurol. 2022;269(4):1996\u20132003.","journal-title":"J Neurol"},{"issue":"1","key":"5097_CR33","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","volume":"24","author":"BP Trewin","year":"2025","unstructured":"Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S. MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev. 2025;24(1):103693.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"5097_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.clineuro.2010.04.014","volume":"112","author":"M Bock","year":"2010","unstructured":"Bock M, Brandt AU, Dorr J, Kraft H, Weinges-Evers N, Gaede G, Pfueller CF, Herges K, Radbruch H, Ohlraun S, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg. 2010;112(8):647\u201352.","journal-title":"Clin Neurol Neurosurg"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05097-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:11:52Z","timestamp":1790637112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5097"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05097-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research adhered to the principles of the Declaration of Helsinki and its ethical guidelines. Approval for this study was obtained from the Medical Ethics Committee of the Chinese People\u2019s Liberation Army General Hospital (S2026-404-01). All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"603"}}